Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2017

Open Access 01-12-2017 | Research article

Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis

Authors: Carol M. Artlett, Sihem Sassi-Gaha, Jennifer L. Hope, Carol A. Feghali-Bostwick, Peter D. Katsikis

Published in: Arthritis Research & Therapy | Issue 1/2017

Login to get access

Abstract

Background

Despite the important role that microRNAs (miRNAs) play in immunity and inflammation, their involvement in systemic sclerosis (SSc) remains poorly characterized. miRNA-155 (miR-155) plays a role in pulmonary fibrosis and its expression can be induced with interleukin (IL)-1β. SSc fibroblasts have activated inflammasomes that are integrally involved in mediating the myofibroblast phenotype. In light of this, we investigated whether miR-155 played a role in SSc and if its expression was dependent on inflammasome activation.

Methods

miR-155 expression was confirmed in SSc dermal and lung fibroblasts by quantitative polymerase chain reaction (PCR). Wild-type and NLRP3-deficient murine fibroblasts were utilized to explore the regulation of miR-155 during inflammasome activation. miR-155-deficient fibroblasts and retroviral transductions with a miR-155 expression or control vectors were used to understand the contribution of miR-155 in fibrosis.

Results

miR-155 was significantly increased and the highest expressing miRNA in SSc lung fibroblasts. Its expression was dependent on inflammasome activation as miR-155 expression could be blocked when inflammasome signaling was inhibited. In the absence of miR-155, inflammasome-mediated collagen synthesis could not be induced but was restored when miR-155 was expressed in miR-155-deficient fibroblasts.

Conclusions

miR-155 is upregulated in SSc. These results suggest that the inflammasome promotes the expression of miR-155 and that miR-155 is a critical miRNA that drives fibrosis.
Literature
1.
go back to reference Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis. 2008;66:198–202.PubMed Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis. 2008;66:198–202.PubMed
2.
go back to reference Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem. 1995;270:3423–8.CrossRefPubMed Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem. 1995;270:3423–8.CrossRefPubMed
3.
go back to reference Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheum Rep. 2007;9:136–43.CrossRef Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheum Rep. 2007;9:136–43.CrossRef
4.
go back to reference Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev. 2002;3:349–63.CrossRef Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev. 2002;3:349–63.CrossRef
5.
go back to reference Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger Jr TA. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007;34:104–9.PubMed Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger Jr TA. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007;34:104–9.PubMed
6.
go back to reference Parodi A, Drosera M, Barbieri L, Rebora A. Scleroderma subsets are best detected by the simultaneous analysis of the autoantibody profile using commercial ELISA. Dermatology. 2002;204:29–32.CrossRefPubMed Parodi A, Drosera M, Barbieri L, Rebora A. Scleroderma subsets are best detected by the simultaneous analysis of the autoantibody profile using commercial ELISA. Dermatology. 2002;204:29–32.CrossRefPubMed
7.
go back to reference Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD. The inflammasome activating caspase-1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum. 2011;63:3563–74.CrossRefPubMed Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD. The inflammasome activating caspase-1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum. 2011;63:3563–74.CrossRefPubMed
8.
go back to reference Kawashita Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, Masuguchi S, Fukushima S, Inoue Y, Ihn H. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci. 2011;61:67–9.CrossRefPubMed Kawashita Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, Masuguchi S, Fukushima S, Inoue Y, Ihn H. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci. 2011;61:67–9.CrossRefPubMed
9.
go back to reference Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62:1733–43.CrossRefPubMed Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62:1733–43.CrossRefPubMed
10.
go back to reference Li C, He H, Zhu M, Zhao S, Li X. Molecular characterisation of porcine miR-155 and its regulatory roles in the TLR3/TLR4 pathways. Dev Comp Immunol. 2012;39:110–6.CrossRefPubMed Li C, He H, Zhu M, Zhao S, Li X. Molecular characterisation of porcine miR-155 and its regulatory roles in the TLR3/TLR4 pathways. Dev Comp Immunol. 2012;39:110–6.CrossRefPubMed
11.
go back to reference Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27:847–59.CrossRefPubMedPubMedCentral Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27:847–59.CrossRefPubMedPubMedCentral
12.
go back to reference Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316:604–8.CrossRefPubMed Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316:604–8.CrossRefPubMed
13.
go back to reference O’Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33:607–19.CrossRefPubMedPubMedCentral O’Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33:607–19.CrossRefPubMedPubMedCentral
14.
go back to reference Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, et al. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nat Immunol. 2013;14:593–602.CrossRefPubMedPubMedCentral Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, et al. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nat Immunol. 2013;14:593–602.CrossRefPubMedPubMedCentral
15.
go back to reference Bala S, Csak T, Saha B, Zatsiorsky J, Kodys K, Catalano D, Szabo G. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol. 2016;64:1378–87.CrossRefPubMedPubMedCentral Bala S, Csak T, Saha B, Zatsiorsky J, Kodys K, Catalano D, Szabo G. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol. 2016;64:1378–87.CrossRefPubMedPubMedCentral
16.
go back to reference Zheng L, Xu CC, Chen WD, Shen WL, Ruan CC, Zhu LM, Zhu DL, Gao PJ. MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem Biophys Res Commun. 2010;400:483–8.CrossRefPubMed Zheng L, Xu CC, Chen WD, Shen WL, Ruan CC, Zhu LM, Zhu DL, Gao PJ. MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem Biophys Res Commun. 2010;400:483–8.CrossRefPubMed
17.
go back to reference Yang LL, Liu JQ, Bai XZ, Fan L, Han F, Jia WB, Su LL, Shi JH, Tang CW, Hu DH. Acute downregulation of miR-155 at wound sites leads to a reduced fibrosis through attenuating inflammatory response. Biochem Biophys Res Commun. 2014;453:153–9.CrossRefPubMed Yang LL, Liu JQ, Bai XZ, Fan L, Han F, Jia WB, Su LL, Shi JH, Tang CW, Hu DH. Acute downregulation of miR-155 at wound sites leads to a reduced fibrosis through attenuating inflammatory response. Biochem Biophys Res Commun. 2014;453:153–9.CrossRefPubMed
18.
go back to reference Pottier N, Maurin T, Chevalier B, Puissegur MP, Lebrigand K, Robbe-Sermesant K, Bertero T, Lino Cardenas CL, Courcot E, Rios G, et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoSOne. 2009;4:e6718.CrossRef Pottier N, Maurin T, Chevalier B, Puissegur MP, Lebrigand K, Robbe-Sermesant K, Bertero T, Lino Cardenas CL, Courcot E, Rios G, et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoSOne. 2009;4:e6718.CrossRef
19.
go back to reference Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28:6773–84.CrossRefPubMedPubMedCentral Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28:6773–84.CrossRefPubMedPubMedCentral
20.
go back to reference Masi AT, Rodnan GP, Medsger TA, Altman RD, D’Angelo WA, Fries JF, LeRoy EC, Kirsner AB, Mackenzie AH, McShane DJ, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581–90.CrossRef Masi AT, Rodnan GP, Medsger TA, Altman RD, D’Angelo WA, Fries JF, LeRoy EC, Kirsner AB, Mackenzie AH, McShane DJ, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581–90.CrossRef
21.
go back to reference LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMed LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMed
23.
go back to reference Zhang D, Cui Y, Li B, Luo X, Li B, Tang Y. miR-155 regulates high glucose-induced cardiac fibrosis via the TGF-beta signaling pathway. Molec BioSystems. 2016;13:215–24.CrossRef Zhang D, Cui Y, Li B, Luo X, Li B, Tang Y. miR-155 regulates high glucose-induced cardiac fibrosis via the TGF-beta signaling pathway. Molec BioSystems. 2016;13:215–24.CrossRef
24.
go back to reference Brown CA, Toth AP, Magnussen B. Clinical benefits of intra-articular anakinra for arthrofibrosis. Orthopedics. 2010;33:877.PubMed Brown CA, Toth AP, Magnussen B. Clinical benefits of intra-articular anakinra for arthrofibrosis. Orthopedics. 2010;33:877.PubMed
25.
go back to reference Magnussen RA, Brown CA, Lawrence TJ, Toth AP. Intra-articular anakinra for the treatment of persistent inflammation and arthrofibrosis following anterior cruciate ligament reconstruction. Duke Orthopedic J. 2011;1:51–6. Magnussen RA, Brown CA, Lawrence TJ, Toth AP. Intra-articular anakinra for the treatment of persistent inflammation and arthrofibrosis following anterior cruciate ligament reconstruction. Duke Orthopedic J. 2011;1:51–6.
26.
go back to reference Lan HY, Nikolic-Paterson DJ, Mu W, Vannice JL, Atkins RC. Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int. 1995;47:1303–9.CrossRefPubMed Lan HY, Nikolic-Paterson DJ, Mu W, Vannice JL, Atkins RC. Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int. 1995;47:1303–9.CrossRefPubMed
27.
go back to reference Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VFJ, Lagente V, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest. 2007;117:3786–99.PubMedPubMedCentral Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VFJ, Lagente V, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest. 2007;117:3786–99.PubMedPubMedCentral
28.
go back to reference Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, Le Toquin S, Bensadoun H, Larousserie F, Silvera S, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116:4070–6.CrossRefPubMed Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, Le Toquin S, Bensadoun H, Larousserie F, Silvera S, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116:4070–6.CrossRefPubMed
29.
go back to reference Adam Z, Szturz P, Buckova P, Cervinkova I, Koukalova R, Rehak Z, Krejci M, Pour L, Zahradova L, Hajek R, et al. Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease—case study and a review of literature. Vnitr Lek. 2012;58:313–8.PubMed Adam Z, Szturz P, Buckova P, Cervinkova I, Koukalova R, Rehak Z, Krejci M, Pour L, Zahradova L, Hajek R, et al. Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease—case study and a review of literature. Vnitr Lek. 2012;58:313–8.PubMed
30.
go back to reference Barlo NP, van Moorsel CH, Korthagen NM, Heron M, Rijkers GT, Ruven HJ, van den Bosch JM, Grutters JC. Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1beta in idiopathic pulmonary fibrosis. Clin Exp Immunol. 2011;166:346–51.CrossRefPubMedPubMedCentral Barlo NP, van Moorsel CH, Korthagen NM, Heron M, Rijkers GT, Ruven HJ, van den Bosch JM, Grutters JC. Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1beta in idiopathic pulmonary fibrosis. Clin Exp Immunol. 2011;166:346–51.CrossRefPubMedPubMedCentral
31.
go back to reference Korthagen NM, van Moorsel CH, Kazemier KM, Ruven HJ, Grutters JC. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics. 2012;64:371–7.CrossRefPubMedPubMedCentral Korthagen NM, van Moorsel CH, Kazemier KM, Ruven HJ, Grutters JC. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics. 2012;64:371–7.CrossRefPubMedPubMedCentral
32.
go back to reference Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Eng J Med. 2009;360:2426–37.CrossRef Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Eng J Med. 2009;360:2426–37.CrossRef
33.
go back to reference Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever—are they more frequent? Semin Arthritis Rheum. 2007;36:316–21.CrossRefPubMed Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever—are they more frequent? Semin Arthritis Rheum. 2007;36:316–21.CrossRefPubMed
34.
go back to reference Paydas S, Gokel Y. Different renal pathologies associated with hypothyroidism. Renal Fail. 2002;24:595–600.CrossRef Paydas S, Gokel Y. Different renal pathologies associated with hypothyroidism. Renal Fail. 2002;24:595–600.CrossRef
Metadata
Title
Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis
Authors
Carol M. Artlett
Sihem Sassi-Gaha
Jennifer L. Hope
Carol A. Feghali-Bostwick
Peter D. Katsikis
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2017
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-017-1331-z

Other articles of this Issue 1/2017

Arthritis Research & Therapy 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.